Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CFO Benjamin Hohl sold 900 shares of the firm's stock in a transaction on Monday, December 30th. The stock was sold at an average price of $22.51, for a total transaction of $20,259.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Benjamin Hohl also recently made the following trade(s):
- On Friday, December 27th, Benjamin Hohl sold 3,350 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.15, for a total value of $74,202.50.
- On Wednesday, November 27th, Benjamin Hohl sold 5,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $24.89, for a total transaction of $130,672.50.
- On Monday, October 28th, Benjamin Hohl sold 6,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $28.56, for a total value of $178,500.00.
- On Friday, October 18th, Benjamin Hohl sold 814 shares of Enliven Therapeutics stock. The stock was sold at an average price of $30.00, for a total transaction of $24,420.00.
- On Friday, October 4th, Benjamin Hohl sold 10,218 shares of Enliven Therapeutics stock. The shares were sold at an average price of $27.51, for a total value of $281,097.18.
- On Monday, October 7th, Benjamin Hohl sold 1,270 shares of Enliven Therapeutics stock. The shares were sold at an average price of $27.51, for a total transaction of $34,937.70.
Enliven Therapeutics Stock Performance
Target More Reliable Returns in 2025
From Unstoppable Prosperity | Ad
[LIVE] How the Pros are Trading Options in 2025
Charles Payne reveals beginner-friendly options strategies for the New Year
Just click here to claim your seat at the LIVE Power of Options event
Shares of Enliven Therapeutics stock opened at $22.50 on Wednesday. The stock has a market capitalization of $1.10 billion, a price-to-earnings ratio of -11.84 and a beta of 1.02. The company has a fifty day moving average of $25.33 and a 200-day moving average of $24.29. Enliven Therapeutics, Inc. has a 52-week low of $10.90 and a 52-week high of $30.03.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of ELVN. Quest Partners LLC raised its holdings in Enliven Therapeutics by 87.3% during the 2nd quarter. Quest Partners LLC now owns 1,592 shares of the company's stock valued at $37,000 after buying an additional 742 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of Enliven Therapeutics by 64.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 9,085 shares of the company's stock worth $232,000 after acquiring an additional 3,559 shares during the last quarter. SG Americas Securities LLC bought a new stake in Enliven Therapeutics during the 3rd quarter valued at about $256,000. Verition Fund Management LLC bought a new stake in shares of Enliven Therapeutics during the third quarter valued at approximately $271,000. Finally, The Manufacturers Life Insurance Company purchased a new position in shares of Enliven Therapeutics in the second quarter worth $322,000. 95.08% of the stock is owned by institutional investors.
Analyst Ratings Changes
Several equities research analysts recently weighed in on the company. Robert W. Baird lifted their price objective on Enliven Therapeutics from $32.00 to $40.00 and gave the stock an "outperform" rating in a report on Friday, November 15th. HC Wainwright reaffirmed a "buy" rating and issued a $37.00 price target on shares of Enliven Therapeutics in a report on Tuesday, October 1st. Finally, BTIG Research started coverage on shares of Enliven Therapeutics in a research note on Friday, December 13th. They issued a "buy" rating and a $42.00 target price on the stock. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $38.25.
View Our Latest Stock Report on ELVN
Enliven Therapeutics Company Profile
(
Get Free Report)
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
